P
Pablo Maroto
Researcher at Hospital de Sant Pau
Publications - 122
Citations - 4940
Pablo Maroto is an academic researcher from Hospital de Sant Pau. The author has contributed to research in topics: Sunitinib & Prostate cancer. The author has an hindex of 25, co-authored 114 publications receiving 3613 citations. Previous affiliations of Pablo Maroto include Services Hospital & Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Toni K. Choueiri,Bernard Escudier,Thomas Powles,Paul N. Mainwaring,Brian I. Rini,Frede Donskov,Hans J. Hammers,Thomas E. Hutson,Jae-Lyun Lee,Katriina Peltola,Bruce J. Roth,Georg A. Bjarnason,Lajos Géczi,Bhumsuk Keam,Pablo Maroto,Daniel Y.C. Heng,Manuela Schmidinger,Philip W. Kantoff,Anne E. Borgman-Hagey,Colin Hessel,Christian Scheffold,Gisela Schwab,Nizar M. Tannir,Robert J. Motzer +23 more
TL;DR: Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.
Journal ArticleDOI
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer,Boris Alekseev,Sun Young Rha,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,Evgeny Kopyltsov,María José Méndez-Vidal,Vadim Kozlov,Anna Alyasova,Sung Hoo Hong,Anil Kapoor,Teresa Alonso Gordoa,Jaime R. Merchan,Eric Winquist,Pablo Maroto,Jeffrey C. Goh,Miso Kim,Howard Gurney,Vijay Patel,Avivit Peer,Giuseppe Procopio,Toshio Takagi,Bohuslav Melichar,Frederic Rolland,Ugo De Giorgi,Shirley Wong,Jens Bedke,Manuela Schmidinger,Corina E. Dutcus,Alan D. Smith,Lea Dutta,Kalgi Mody,Rodolfo F. Perini,Dongyuan Xing,Toni K. Choueiri +37 more
TL;DR: In this article, Lenvatinib in combination with pembrolizumab or everolimus has been shown to have activity against advanced renal cell carcinoma (RCC).
Journal ArticleDOI
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
Maria De Santis,Joaquim Bellmunt,Graham M. Mead,J. Martijn Kerst,Michael F. Leahy,Pablo Maroto,Thierry Gil,Sandrine Marreaud,Gedske Daugaard,Iwona Skoneczna,Sandra Collette,Julie Lorent,Ronald de Wit,Richard Sylvester +13 more
TL;DR: There were no significant differences in efficacy between the two treatment groups, and the incidence of severe acute toxicities was higher for those receiving M-CAVI.
Journal ArticleDOI
Risk-adapted management for patients with clinical stage I seminoma : The second spanish germ cell cancer cooperative group study
Jorge Aparicio,José R. Germà,Xavier Garcia del Muro,Pablo Maroto,Jose Angel Arranz,A. Saenz,Agustin Barnadas,J. Dorca,Josep Guma,David Olmos,Roma Bastus,Joan Carles,D. Almenar,Miguel Ángel Martín Sánchez,Luis Paz-Ares,Juan J. Satrústegui,Begoña Mellado,Ana Balil,Marta López-Brea,Alfredo Sanchez +19 more
TL;DR: Adjuvant carboplatin is effective in reducing the relapse rate in patients with stage I seminoma and risk factors and should be considered an alternative to systematic approaches, such as irradiation, chemotherapy, or surveillance.
Journal ArticleDOI
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
Sumanta K. Pal,Jonathan E. Rosenberg,Jean H. Hoffman-Censits,Raanan Berger,David I. Quinn,Matthew D. Galsky,Juergen Wolf,Christian Dittrich,Bhumsuk Keam,Jean Pierre Delord,Jan H.M. Schellens,Gwenaelle Gravis,J. Medioni,Pablo Maroto,Virote Sriuranpong,Chaiyut Charoentum,Howard A. Burris,Viktor Grünwald,Daniel P. Petrylak,Ulka N. Vaishampayan,Eliahu Gez,Ugo De Giorgi,Jae-Lyun Lee,Jens Voortman,Sumati Gupta,Sunil Sharma,Amir Mortazavi,David J. Vaughn,Randi Isaacs,Katie Parker,Xueying Chen,Kun Yu,Dale Porter,Diana Graus Porta,Dean F. Bajorin +34 more
TL;DR: BJJ398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease, highlighting putative mechanisms of resistance to the agent, which may be useful in following disease status.